Novo Nordisk A/S shares rose last week despite overall market trends.
Stock AI’s forecasts:
🔴 -7.1% short-term ⬇️
🟢 +1.0% long-term ⬆️
Stock AI’s (NVO) Forecast get (+9.6% Profit)
StockAI’s analysis delivers real-world results. On 07 March 2024, $NVO ($137.5), StockAI predicted a long-term 🔴 sell signal. It was accurate: 1 month later price dropped to $124.3 (🔴-9.6%). Selling NVO on this signal yielded a +9.6% profit 💰💰.
NVO-Novo Nordisk A/S News
🟢 Novo Nordisk A/S shares rose 1.5% on Friday, reaching $126.13 during trading.
🔴 Novo Nordisk A/S share price dropped 0.2% on Thursday, trading as low as $124.13.
🟢 Novo Nordisk A/S stock was up 1.1% during trading on Friday, reaching $127.30.
🔴 Twin Capital Management Inc. bought 2,060 shares of Novo Nordisk A/S during the fourth quarter.
🟢 Perigon Wealth Management LLC increased its holdings in Novo Nordisk A/S by 65.1% during the 4th quarter.
🔴 Dakota Wealth Management lowered its stake in Novo Nordisk A/S by 5.0% in the 4th quarter.
Novo Nordisk A/S stock has seen a mix of positive and negative news recently, with some trading days showing gains while others showing declines. Despite the fluctuations, the overall long-term forecast suggests a potential 1.0% increase. However, the short-term forecast predicts a 7.1% decrease in the stock price.
The rise in share price on Friday could be attributed to increased trading volume and positive market sentiment. On the other hand, the decrease in share price on Thursday may have been influenced by lower trading volume and market uncertainties.
Investors should closely monitor the news surrounding Novo Nordisk A/S and consider the impact of each development on the stock price. While short-term fluctuations are common, the long-term forecast indicates a positive outlook for the company.
NVO-Novo Nordisk A/S Analyst Ratings
In recent analyst ratings for Novo Nordisk A/S (NYSE:NVO) stock, there have been some notable changes:
📈 Credit Suisse analysts upgraded their rating on NVO stock from Neutral to Outperform and set a target price of $130.
📉 Deutsche Bank analysts downgraded their rating on NVO stock from Buy to Hold and lowered the target price from $135 to $120.
📈 Morgan Stanley analysts raised their rating on NVO stock from Equal Weight to Overweight and increased the target price from $125 to $140.
These recent analyst ratings indicate a mix of positive and negative sentiment towards Novo Nordisk A/S stock, with varying outlooks on the potential performance of the company.
Sources:
1. Credit Suisse
2. Deutsche Bank
3. Morgan Stanley
4. MarketWatch
5. Nasdaq
Disclaimer
Investors may consider the AI predictions and news summaries as one factor in their investment decisions alongside their own research and risk tolerance.
Ready to analyze your own portfolio?
Get the same AI-powered insights for any stock you choose. It's easy!
